{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:45:19Z","timestamp":1792813519363,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.cmi.2021.08.007","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T23:25:48Z","timestamp":1628897148000},"page":"31-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Pretomanid for tuberculosis: a systematic review"],"prefix":"10.1016","volume":"28","author":[{"given":"Tinne","family":"Gils","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutgarde","family":"Lynen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouke C.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Van Deun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Decroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2021.08.007_bib1","series-title":"Global tuberculosis report 2020","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.cmi.2021.08.007_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5588\/ijtld.17.0660","article-title":"Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs","volume":"22","author":"Van Deun","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.cmi.2021.08.007_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5588\/ijtld.19.0062","article-title":"Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose","volume":"24","author":"Hong","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.cmi.2021.08.007_bib4","series-title":"WHO Consolidated guidelines on tuberculosis. Module 4: treatment. Drug resistant tuberculosis treatment","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.cmi.2021.08.007_bib5","doi-asserted-by":"crossref","first-page":"1902383","DOI":"10.1183\/13993003.02383-2019","article-title":"Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients","author":"Nimmo","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2021.08.007_bib6","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1164\/rccm.201909-1819LE","article-title":"Bedaquiline-resistant tuberculosis: dark clouds on the horizon","volume":"201","author":"Andres","year":"2020","journal-title":"Am J Resp Critl Care Med"},{"key":"10.1016\/j.cmi.2021.08.007_bib7","series-title":"Rapid Communication: key changes to the treatment of drug-resistant tuberculosis","author":"World Health Organization","year":"2019"},{"key":"10.1016\/j.cmi.2021.08.007_bib8","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.1164571","article-title":"PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release","volume":"322","author":"Singh","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.cmi.2021.08.007_bib9","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A\u00a0small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2021.08.007_bib10","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1128\/AAC.49.6.2289-2293.2005","article-title":"Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis","volume":"49","author":"Tyagi","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.08.007_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4161\/cib.2.3.7926","article-title":"The mechanism of action of PA-824: novel insights from transcriptional profiling","volume":"23","author":"Manjunatha","year":"2009","journal-title":"Commun Integr Biol"},{"key":"10.1016\/j.cmi.2021.08.007_bib12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40267-020-00743-9","article-title":"Pretomanid in drug-resistant tuberculosis: a profile of its use","volume":"36","author":"Shirley","year":"2020","journal-title":"Drugs Ther Perspect"},{"key":"10.1016\/j.cmi.2021.08.007_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00021-19","article-title":"Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis","volume":"63","author":"Xu","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.08.007_bib14","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1128\/AAC.00106-09","article-title":"Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects","volume":"53","author":"Ginsberg","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.08.007_bib15","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1128\/AAC.00798-13","article-title":"Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects","volume":"57","author":"Winter","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.08.007_bib16","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","article-title":"Pretomanid: first approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2021.08.007_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01196-20","article-title":"Pretomanid pharmacokinetics in the presence of rifamycins: interim results from a randomized trial among patients with tuberculosis","volume":"65","author":"Ignatius","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.08.007_bib18","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1128\/AAC.00112-09","article-title":"Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects","volume":"53","author":"Ginsberg","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.08.007_bib19","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1128\/AAC.02632-12","article-title":"Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects","volume":"57","author":"Winter","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.08.007_bib20","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2021.08.007_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.cmi.2021.08.007_bib22","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2021.08.007_bib23","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2013"},{"key":"10.1016\/j.cmi.2021.08.007_bib24","series-title":"Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27\u201329 October 2020","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.cmi.2021.08.007_bib25","series-title":"Definitions and reporting framework for tuberculosis \u2013 2013 revision","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.cmi.2021.08.007_bib26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5588\/ijtld.20.0513","article-title":"A\u00a0partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB","volume":"25","author":"Tweed","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.cmi.2021.08.007_bib27","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.01354-09","article-title":"Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients","volume":"54","author":"Diacon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.08.007_bib28","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1128\/AAC.06125-11","article-title":"Phase II dose-ranging trial of the early bactericidal activity of PA-824","volume":"566","author":"Diacon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.08.007_bib29","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(12)61080-0","article-title":"14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial","volume":"380","author":"Diacon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2021.08.007_bib30","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1164\/rccm.201410-1801OC","article-title":"Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline","volume":"191","author":"Diacon","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2021.08.007_bib31","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/S0140-6736(14)62002-X","volume":"385","author":"Dawson","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2021.08.007_bib32","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S2213-2600(19)30366-2","article-title":"Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial","volume":"7","author":"Tweed","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2021.08.007_bib33","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-Resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.08.007_bib35","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1128\/AAC.05293-11","article-title":"Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis","volume":"55","author":"Tasneen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.08.007_bib36","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/S2213-2600(19)30473-4","article-title":"Tuberculosis treatment: one-shot approach or cascade of regimens?","volume":"8","author":"Decroo","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2021.08.007_bib37","series-title":"Conference on retroviruses and opportunistic infections","article-title":"Final results of the NIX-TB clinical study of BPaL regimen for highly resistant TB","author":"Conradie","year":"2021"},{"key":"10.1016\/j.cmi.2021.08.007_bib38","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3201\/eid2701.203766","article-title":"Novel 6-month treatment for drug-resistant tuberculosis, United States","volume":"271","author":"Haley","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2021.08.007_bib39","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMc1815121","article-title":"Bedaquiline microheteroresistance after cessation of tuberculosis treatment","volume":"380","author":"de Vos","year":"2019","journal-title":"NEJM"},{"key":"10.1016\/j.cmi.2021.08.007_bib40","series-title":"Dovprela (previoulsy Pretomanid FGK) [Internet]","year":"2021"},{"key":"10.1016\/j.cmi.2021.08.007_bib41","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1128\/AAC.00308-15","article-title":"Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in\u00a0vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis","volume":"59","author":"Haver","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.08.007_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkaa136","article-title":"Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid","author":"Kadura","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2021.08.007_bib43","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S1472-9792(08)70038-6","article-title":"The early bactericidal activity of anti-tuberculosis drugs: a literature review","volume":"88","author":"Donald","year":"2008","journal-title":"Tuberculosis"},{"key":"10.1016\/j.cmi.2021.08.007_bib44","series-title":"Drug-resistant TB clinical trial ends enrolment early after positive initial data [press release]","author":"M\u00e9decins Sans Fronti\u00e8res","year":"2021"},{"key":"10.1016\/j.cmi.2021.08.007_bib45","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10096-019-03551-w","article-title":"Comparison of in\u00a0vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis","volume":"38","author":"Wen","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2021.08.007_bib46","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","article-title":"Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial","volume":"7","author":"von Groote-Bidlingmaier","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2021.08.007_bib47","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2021.08.007_bib48","series-title":"Clinical and research information on drug-induced liver injury","author":"LiverTox","year":"2012"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2100464X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2100464X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T10:22:19Z","timestamp":1753611739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X2100464X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1198743X2100464X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2021.08.007","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretomanid for tuberculosis: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2021.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}